Lung cancer screening saves lives, yet most Americans who qualify never get scanned, and new reporting is asking why. The New York Times examined why so many eligible people still are not screened, from missed referrals to fear of the results. Gaps in lung cancer screening were spotlighted at the ASCO Quality Care Symposium, where experts said far too few patients are tested. A new dataset mapping eligibility for low-dose CT scans could help close the gap.
Lung cancer kills more Americans than any other cancer, and low-dose computed tomography offers a proven way to catch it early in people at high risk. Guidelines recommend annual scans for longtime smokers and former smokers who meet age and smoking-history criteria. Yet screening rates remain strikingly low, a failure that experts say costs thousands of lives each year. Understanding why eligible people skip the scan has become an urgent public health question.
The New York Times investigation into why so many people still are not screened for lung cancer points to a tangle of causes. Many eligible patients have never heard that the test exists, and some primary care doctors do not routinely bring it up. Others worry about the cost, the radiation involved or what a suspicious finding might mean. Stigma around smoking adds another barrier, making some patients reluctant to identify themselves as candidates.
The problem drew fresh attention at the ASCO Quality Care Symposium, where presenters highlighted gaps in lung cancer screening across health systems. Data shared at the meeting showed wide variation in who gets referred and who follows through. Experts at the symposium argued that screening cannot succeed as a test alone; it needs navigators, reminders and clear pathways from a positive result to treatment.
A new dataset could give that effort a sharper map. Researchers have built a dataset identifying people eligible for LDCT lung cancer screening, giving health systems a clearer picture of where the unscreened population lives. By mapping eligibility at a granular level, the tool could help clinics target outreach to the neighborhoods and groups most likely to be missed. Public health officials say such data is essential for turning guidelines into actual scans.
The low uptake is especially frustrating to experts because the scan is one of the few cancer tests with strong evidence behind it. Unlike mammograms and colonoscopies, which are now routine parts of preventive care, the lung scan has never had a comparable public awareness campaign. Opinion writers argue that this visibility gap helps explain why far too few patients are being tested, and they say the medical community must take responsibility for promoting the test as aggressively as it promotes others.
- Lung cancer is the deadliest cancer, yet screening uptake remains very low.
- Many eligible patients have never been told the test exists.
- The ASCO Quality Care Symposium spotlighted wide gaps in referrals and follow-through.
- A new dataset maps who is eligible for low-dose CT screening.
- Experts say navigators, reminders and outreach are needed to close the gap.
What Closing the Lung Cancer Screening Gap Will Take
Opinion pieces in the radiology press have been blunt: far too few patients are being screened, and the medical community bears part of the blame. Commentators argue that lung cancer screening has never received the public awareness campaigns that made mammograms and colonoscopies routine. They also point to fragmented care, where no single doctor owns the responsibility of ordering the scan. Without a coordinated push, they warn, the gap will persist.
The path forward is becoming clearer. Health systems are experimenting with electronic reminders, mailed invitations and dedicated screening coordinators. If the new eligibility maps are widely adopted, outreach could become far more precise. For a test that can catch the nation’s deadliest cancer at a curable stage, advocates say the goal is simple: make the scan as ordinary as a blood pressure check. If outreach becomes as routine as the reminders patients already get for other cancer tests, experts believe screening rates could climb substantially.